{ "format" : "linked-data-api", "version" : "0.2", "result" : {"_about" : "https://eldaddp.azurewebsites.net/answeredquestions.text?max-ddpModified.=2018-11-20T16%3A56%3A04.213Z&min-ddpCreated=2018-11-14T21%3A03%3A27.527Z&min-ddpModified.=2018-11-20T11%3A57%3A01.953Z&hansardHeading=HIV+Infection%3A+Drugs", "definition" : "https://eldaddp.azurewebsites.net/meta/answeredquestions.text?max-ddpModified.=2018-11-20T16%3A56%3A04.213Z&min-ddpCreated=2018-11-14T21%3A03%3A27.527Z&min-ddpModified.=2018-11-20T11%3A57%3A01.953Z&hansardHeading=HIV+Infection%3A+Drugs", "extendedMetadataVersion" : "https://eldaddp.azurewebsites.net/answeredquestions.text?max-ddpModified.=2018-11-20T16%3A56%3A04.213Z&min-ddpCreated=2018-11-14T21%3A03%3A27.527Z&_metadata=all&min-ddpModified.=2018-11-20T11%3A57%3A01.953Z&hansardHeading=HIV+Infection%3A+Drugs", "first" : "https://eldaddp.azurewebsites.net/answeredquestions.text?_page=0&max-ddpModified.=2018-11-20T16%3A56%3A04.213Z&min-ddpCreated=2018-11-14T21%3A03%3A27.527Z&min-ddpModified.=2018-11-20T11%3A57%3A01.953Z&hansardHeading=HIV+Infection%3A+Drugs", "hasPart" : "https://eldaddp.azurewebsites.net/answeredquestions.text?max-ddpModified.=2018-11-20T16%3A56%3A04.213Z&min-ddpCreated=2018-11-14T21%3A03%3A27.527Z&min-ddpModified.=2018-11-20T11%3A57%3A01.953Z&hansardHeading=HIV+Infection%3A+Drugs", "isPartOf" : "https://eldaddp.azurewebsites.net/answeredquestions.text?max-ddpModified.=2018-11-20T16%3A56%3A04.213Z&min-ddpCreated=2018-11-14T21%3A03%3A27.527Z&min-ddpModified.=2018-11-20T11%3A57%3A01.953Z&hansardHeading=HIV+Infection%3A+Drugs", "items" : [{"_about" : "http://data.parliament.uk/resources/1007772", "AnsweringBody" : [{"_value" : "Department of Health and Social Care"}
      ], "answer" : {"_about" : "http://data.parliament.uk/resources/1007772/answer", "answerText" : {"_value" : "<p>In line with the guidance governing research, the HIV Pre-Exposure Prophylaxis (PrEP) Impact Trial is currently unable to provide any detailed breakdown of information about participants. This is to preserve the integrity of the emerging data. A planned interim analysis including further demographic breakdown is planned early next year.<\/p><p> <\/p><p>An evaluation report will be available after the completion of the trial in 2021 which is expected to include the facilitators and barriers to accessing HIV pre-exposure prophylaxis across all groups, including women.<\/p>"}
        , "answeringMember" : {"_about" : "http://data.parliament.uk/members/4067", "label" : {"_value" : "Biography information for Steve Brine"}
        }
        , "answeringMemberConstituency" : {"_value" : "Winchester"}
        , "answeringMemberPrinted" : {"_value" : "Steve Brine"}
        , "dateOfAnswer" : {"_value" : "2018-11-20", "_datatype" : "dateTime"}
        , "groupedQuestionUIN" : [{"_value" : "191930"}
        , {"_value" : "191931"}
        , {"_value" : "191932"}
        ], "isMinisterialCorrection" : {"_value" : "false", "_datatype" : "boolean"}
        , "questionFirstAnswered" : [{"_value" : "2018-11-20T15:03:05.303Z", "_datatype" : "dateTime"}
        ]}
      , "answeringDeptId" : {"_value" : "17"}
      , "answeringDeptShortName" : {"_value" : "Health and Social Care"}
      , "answeringDeptSortName" : {"_value" : "Health and Social Care"}
      , "date" : {"_value" : "2018-11-15", "_datatype" : "dateTime"}
      , "hansardHeading" : {"_value" : "HIV Infection: Drugs"}
      , "houseId" : {"_value" : "1"}
      , "legislature" : [{"_about" : "http://data.parliament.uk/terms/25259", "prefLabel" : {"_value" : "House of Commons"}
      }
      ], "questionText" : "To ask the Secretary of State for Health and Social Care, pursuant to the Answer of 21 June 2018 to Question 153280 on HIV Infection: Drugs, if he will publish the review of risk factors and associated vulnerabilities among women recruited to the trial.", "registeredInterest" : {"_value" : "false", "_datatype" : "boolean"}
      , "tablingMember" : {"_about" : "http://data.parliament.uk/members/4267", "label" : {"_value" : "Biography information for Sarah Champion"}
      }
      , "tablingMemberConstituency" : {"_value" : "Rotherham"}
      , "tablingMemberPrinted" : [{"_value" : "Sarah Champion"}
      ], "uin" : "191929"}
    , {"_about" : "http://data.parliament.uk/resources/1007773", "AnsweringBody" : [{"_value" : "Department of Health and Social Care"}
      ], "answer" : {"_about" : "http://data.parliament.uk/resources/1007773/answer", "answerText" : {"_value" : "<p>In line with the guidance governing research, the HIV Pre-Exposure Prophylaxis (PrEP) Impact Trial is currently unable to provide any detailed breakdown of information about participants. This is to preserve the integrity of the emerging data. A planned interim analysis including further demographic breakdown is planned early next year.<\/p><p> <\/p><p>An evaluation report will be available after the completion of the trial in 2021 which is expected to include the facilitators and barriers to accessing HIV pre-exposure prophylaxis across all groups, including women.<\/p>"}
        , "answeringMember" : {"_about" : "http://data.parliament.uk/members/4067", "label" : {"_value" : "Biography information for Steve Brine"}
        }
        , "answeringMemberConstituency" : {"_value" : "Winchester"}
        , "answeringMemberPrinted" : {"_value" : "Steve Brine"}
        , "dateOfAnswer" : {"_value" : "2018-11-20", "_datatype" : "dateTime"}
        , "groupedQuestionUIN" : [{"_value" : "191929"}
        , {"_value" : "191931"}
        , {"_value" : "191932"}
        ], "isMinisterialCorrection" : {"_value" : "false", "_datatype" : "boolean"}
        , "questionFirstAnswered" : [{"_value" : "2018-11-20T15:03:05.35Z", "_datatype" : "dateTime"}
        ]}
      , "answeringDeptId" : {"_value" : "17"}
      , "answeringDeptShortName" : {"_value" : "Health and Social Care"}
      , "answeringDeptSortName" : {"_value" : "Health and Social Care"}
      , "date" : {"_value" : "2018-11-15", "_datatype" : "dateTime"}
      , "hansardHeading" : {"_value" : "HIV Infection: Drugs"}
      , "houseId" : {"_value" : "1"}
      , "legislature" : [{"_about" : "http://data.parliament.uk/terms/25259", "prefLabel" : {"_value" : "House of Commons"}
      }
      ], "questionText" : "To ask the Secretary of State for Health and Social Care, pursuant to the Answer of 21 June 2018 to Question 153280 on HIV Infection: drugs, if he will publish the outcome of the interviews with women to explore the facilitators and barriers to accessing the HIV pre-exposure prophylaxis.", "registeredInterest" : {"_value" : "false", "_datatype" : "boolean"}
      , "tablingMember" : {"_about" : "http://data.parliament.uk/members/4267", "label" : {"_value" : "Biography information for Sarah Champion"}
      }
      , "tablingMemberConstituency" : {"_value" : "Rotherham"}
      , "tablingMemberPrinted" : [{"_value" : "Sarah Champion"}
      ], "uin" : "191930"}
    , {"_about" : "http://data.parliament.uk/resources/1007775", "AnsweringBody" : [{"_value" : "Department of Health and Social Care"}
      ], "answer" : {"_about" : "http://data.parliament.uk/resources/1007775/answer", "answerText" : {"_value" : "<p>In line with the guidance governing research, the HIV Pre-Exposure Prophylaxis (PrEP) Impact Trial is currently unable to provide any detailed breakdown of information about participants. This is to preserve the integrity of the emerging data. A planned interim analysis including further demographic breakdown is planned early next year.<\/p><p> <\/p><p>An evaluation report will be available after the completion of the trial in 2021 which is expected to include the facilitators and barriers to accessing HIV pre-exposure prophylaxis across all groups, including women.<\/p>"}
        , "answeringMember" : {"_about" : "http://data.parliament.uk/members/4067", "label" : {"_value" : "Biography information for Steve Brine"}
        }
        , "answeringMemberConstituency" : {"_value" : "Winchester"}
        , "answeringMemberPrinted" : {"_value" : "Steve Brine"}
        , "dateOfAnswer" : {"_value" : "2018-11-20", "_datatype" : "dateTime"}
        , "groupedQuestionUIN" : [{"_value" : "191929"}
        , {"_value" : "191930"}
        , {"_value" : "191932"}
        ], "isMinisterialCorrection" : {"_value" : "false", "_datatype" : "boolean"}
        , "questionFirstAnswered" : [{"_value" : "2018-11-20T15:03:05.407Z", "_datatype" : "dateTime"}
        ]}
      , "answeringDeptId" : {"_value" : "17"}
      , "answeringDeptShortName" : {"_value" : "Health and Social Care"}
      , "answeringDeptSortName" : {"_value" : "Health and Social Care"}
      , "date" : {"_value" : "2018-11-15", "_datatype" : "dateTime"}
      , "hansardHeading" : {"_value" : "HIV Infection: Drugs"}
      , "houseId" : {"_value" : "1"}
      , "legislature" : [{"_about" : "http://data.parliament.uk/terms/25259", "prefLabel" : {"_value" : "House of Commons"}
      }
      ], "questionText" : "To ask the Secretary of State for Health and Social Care, pursuant to the Answer of 21 June 2018 to Question 153280 on HIV Infection: Drugs, how many women have joined the HIV pre-exposure prophylaxis impact trial to date.", "registeredInterest" : {"_value" : "false", "_datatype" : "boolean"}
      , "tablingMember" : {"_about" : "http://data.parliament.uk/members/4267", "label" : {"_value" : "Biography information for Sarah Champion"}
      }
      , "tablingMemberConstituency" : {"_value" : "Rotherham"}
      , "tablingMemberPrinted" : [{"_value" : "Sarah Champion"}
      ], "uin" : "191931"}
    , {"_about" : "http://data.parliament.uk/resources/1007776", "AnsweringBody" : [{"_value" : "Department of Health and Social Care"}
      ], "answer" : {"_about" : "http://data.parliament.uk/resources/1007776/answer", "answerText" : {"_value" : "<p>In line with the guidance governing research, the HIV Pre-Exposure Prophylaxis (PrEP) Impact Trial is currently unable to provide any detailed breakdown of information about participants. This is to preserve the integrity of the emerging data. A planned interim analysis including further demographic breakdown is planned early next year.<\/p><p> <\/p><p>An evaluation report will be available after the completion of the trial in 2021 which is expected to include the facilitators and barriers to accessing HIV pre-exposure prophylaxis across all groups, including women.<\/p>"}
        , "answeringMember" : {"_about" : "http://data.parliament.uk/members/4067", "label" : {"_value" : "Biography information for Steve Brine"}
        }
        , "answeringMemberConstituency" : {"_value" : "Winchester"}
        , "answeringMemberPrinted" : {"_value" : "Steve Brine"}
        , "dateOfAnswer" : {"_value" : "2018-11-20", "_datatype" : "dateTime"}
        , "groupedQuestionUIN" : [{"_value" : "191929"}
        , {"_value" : "191930"}
        , {"_value" : "191931"}
        ], "isMinisterialCorrection" : {"_value" : "false", "_datatype" : "boolean"}
        , "questionFirstAnswered" : [{"_value" : "2018-11-20T15:03:05.453Z", "_datatype" : "dateTime"}
        ]}
      , "answeringDeptId" : {"_value" : "17"}
      , "answeringDeptShortName" : {"_value" : "Health and Social Care"}
      , "answeringDeptSortName" : {"_value" : "Health and Social Care"}
      , "date" : {"_value" : "2018-11-15", "_datatype" : "dateTime"}
      , "hansardHeading" : {"_value" : "HIV Infection: Drugs"}
      , "houseId" : {"_value" : "1"}
      , "legislature" : [{"_about" : "http://data.parliament.uk/terms/25259", "prefLabel" : {"_value" : "House of Commons"}
      }
      ], "questionText" : "To ask the Secretary of State for Health and Social Care, pursuant to the Answer of 21 June 2018 to Question 153280 on HIV Infection: Drugs, how many women who are victims of domestic violence have joined the HIV pre-exposure prophylaxis impact trial to date.", "registeredInterest" : {"_value" : "false", "_datatype" : "boolean"}
      , "tablingMember" : {"_about" : "http://data.parliament.uk/members/4267", "label" : {"_value" : "Biography information for Sarah Champion"}
      }
      , "tablingMemberConstituency" : {"_value" : "Rotherham"}
      , "tablingMemberPrinted" : [{"_value" : "Sarah Champion"}
      ], "uin" : "191932"}
    ], "itemsPerPage" : 10, "page" : 0, "startIndex" : 1, "totalResults" : 4, "type" : ["http://purl.org/linked-data/api/vocab#ListEndpoint", "http://purl.org/linked-data/api/vocab#Page"]}
}